ArticleHerz2011
Sorafenib-associated multivessel coronary artery vasospasm.
Article in Herz, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 44 citations in OpenAlex.
- Vascular Toxicities of Cancer Therapies: 2025 Update.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Understanding Sorafenib-Induced Cardiovascular Toxicity: Mechanisms and Treatment Implications.Drug design, development and therapy · 2024Review
- Multimodality imaging approach in a case of vascular toxicity caused by cabozantinib.Radiology case reports · 2024Article
- Examining the Effects of Dasatinib, Sorafenib, and Nilotinib on Vascular Smooth Muscle Cells: Insights into Proliferation, Migration, and Gene Expression Dynamics.Diseases (Basel, Switzerland) · 2023Article
- Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review.Journal of cardiovascular development and disease · 2023Review
- Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma.Biomedicines · 2023Review
- Analysis of Epidemiological Characteristics of New Cardiovascular Diseases in Cancer Patients with Cardiovascular Disease.Journal of oncology · 2022Article
- Relation Between Cancer and Vasospastic Angina.Advances in therapy · 2021Observational
- Cardiotoxic effects of angiogenesis inhibitors.Clinical science (London, England : 1979) · 2021Review
- The Pharmacological Approach to Oncologic Patients with Acute Coronary Syndrome.Journal of clinical medicine · 2020Review
- Vascular toxic effects of cancer therapies.Nature reviews. Cardiology · 2020Review
- Recurrent Coronary Artery Vasospasm in a Patient with Hepatocellular Carcinoma Treated with Sorafenib: a Case Report and Literature Review.Journal of liver cancer · 2020Article
- Is there a role for remote ischemic conditioning in preventing 5-fluorouracil-induced coronary vasospasm?Conditioning medicine · 2019Article
- Cancer and Coronary Artery Disease: Common Associations, Diagnosis and Management Challenges.Current treatment options in oncology · 2019Review
- Coronary Artery Vasospasm Induced by 5-fluorouracil: Proposed Mechanisms, Existing Management Options and Future Directions.Interventional cardiology (London, England) · 2019Review
- Arterial events in cancer patients-the case of acute coronary thrombosis.Journal of thoracic disease · 2018Review
- Multivessel coronary artery spasm in pericarditis.Singapore medical journal · 2018Article
- Interventional Cardio-Oncology: Adding a New Dimension to the Cardio-Oncology Field.Frontiers in cardiovascular medicine · 2018Article
- Management of CAD in Patients with Active Cancer: the Interventional Cardiologists' Perspective.Current cardiology reports · 2017Review
- Cancer as a Risk Factor for Cardiovascular Disease.Current oncology reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiotoxicity associated with cancer treatment is an important field of interest especially as the new class of VEGF signaling pathway inhibitors (VSP) continues to grow. Small molecule tyrosine kinase inhibitors such as sorafenib, sunitinib, and pazopanib inhibit the downstream pathways of all three of the vascular endothelial growth factor receptors (VEGFR 1, 2, and 3). Other targets of these agents include kinases involved in vascular and myocardial homoeostasis. These agents are all known to frequently cause hypertension, their most common side-effect. Myocardial ischemia has also been reported, but the frequency and etiology of VSP-related ischemia is poorly characterized. This manuscript describes the first reported case of sorafenib-associated multivessel coronary vasospasm in a 57-year-old patient with hepatocellular carcinoma. He underwent sorafenib treatment, a tyrosinase inhibitor, 400 mg twice a day. The vasospasm was reversible under nitroglycerin. Possible mechanisms are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.